Loading...
Loading...
PROK| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1.0M |
| Gross Profit | -1.0M |
| Operating Expense | 43.1M |
| Operating I/L | -43.1M |
| Other Income/Expense | 4.5M |
| Interest Income | 4.5M |
| Pretax | -38.5M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | -12.5M |
ProKidney Corp. is a clinical-stage biotechnology company focused on developing cellular therapy candidates. Its flagship product, Renal Autologous Cell Therapy, is currently in Phase III development for the treatment of moderate to severe diabetic kidney disease, with additional Phase II clinical trials underway. The company also has a Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. ProKidney Corp. generates revenue through the development and potential commercialization of its cellular therapy products for the treatment of kidney-related conditions.
